SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

Durham, Stephen R.; Emminger, W.; Kapp, Alexander; Monchy, J. G. R. De; Rak, S.; Scadding, Glenis; Würtzen, Peter Adler; Andersen, Jens S.; Tholstrup, Bente; Riis, B.J.; Dahl, Ronald

doi:10.1016/j.jaci.2011.12.973

Cited by 454 publications

(464 citation statements)

References 31 publications

Supporting

Mentioning

431

Contrasting

Unclassified

Order By: Relevance

“…Disease-modifying therapy has been available for more than 100 years in the form of specific allergen immunotherapy (SIT) (1). SIT has been widely demonstrated to be clinically effective and to provide amelioration of symptoms for periods well in excess of the treatment period (2,3). Prolonged efficacy suggests a fundamental modification of the underlying disease process, which may be regarded as the induction of "tolerance" to the sensitizing allergen.…”

mentioning

confidence: 99%

Mechanisms of Peptide Immunotherapy in Allergic Airways Disease

Larché

2014

Annals ATS

View full text Add to dashboard Cite

Allergen immunotherapy with whole proteins is clinically efficacious but requires a protracted treatment period because of frequent allergic adverse events. A combination of duration of treatment and adverse events leads to poor compliance. Short synthetic peptides containing the major immunodominant T cell epitopes of allergenic proteins have been shown to reduce IgE cross-linking ability, thereby leading to fewer allergic adverse events following their administration to patients with allergies. Peptide immunotherapy has been shown to result in clinically meaningful efficacy in several Phase II, randomized, double-blind, placebo-controlled clinical trials. Exactly how peptide immunotherapy achieves its efficacy remains incompletely understood, but the mechanisms are thought to include immune deviation and induction of regulatory T cells capable of suppressing allergen-specific immune responses. Limited data are available on the effects of peptide therapy on humoral immune responses. Induction of allergen-specific IgG has been observed after peptide therapy, but the levels of antibody induced were much lower than generally seen with the utilization of whole allergen approaches. Thus, the immunological mechanisms of peptide immunotherapy appear to overlap, although not completely, with those seen in whole allergen therapy. Further studies are required to fully elucidate mechanisms of action.

show abstract

mentioning

confidence: 99%

Mechanisms of Peptide Immunotherapy in Allergic Airways Disease

Larché

2014

Annals ATS

View full text Add to dashboard Cite

show abstract

“…Our search strategy identified 1378 unique publications, including over 338 peer-reviewed studies published from inception to June 30, 2015 finally retrieved , of which 18 met the inclusion criteria (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). We excluded the Jacobsen study (38), because the outcome was reported in a subgroup of patients regardless of the treatment received, the Eifan (39) Acquistapace (40), Szepfalusi (41), and Shao (42) studies because they were not long-term studies (<3 years of treatment/follow-up).…”

Section: Resultsmentioning

confidence: 99%

“…The Novembre (25) and Durham (37) studies reported on the outcome, but did not report the crude data, and were only qualitatively assessed. Table 1 shows descriptive data for the 18 systematically reviewed studies (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] and seven adult studies (31-37) included a total of 11 106 patients (1049 children, 10 057 adults), of which 8369 (75.6%) were included only in the Purello D'Ambrosio study (31).…”

Section: Resultsmentioning

confidence: 99%

Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Bona

Plaia

Leto-Barone

et al. 2017

Allergy

View full text Add to dashboard Cite

Background: Guidelines and position papers indicate that allergen immunotherapy (AIT) is the only disease-modifying treatment, including prevention of the onset of new allergen sensitizations. However, this preventive effect was shown by only a few observational studies. Our aim was to systematically review the efficacy of AIT in preventing the onset of new allergen sensitizations. Methods: Computerized bibliographic searches of Medline, EMBASE, and the Cochrane Library (through June 2015) were supplemented with manual searches of reference lists. Observational studies or randomized controlled trials with a longterm observation period were included. Paired reviewers extracted data about study characteristics and assessed biases. The end point was the risk difference in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. The strength of the evidence was graded based on the risk of bias, consistency, and magnitude of effect, according to the GRADE Working Group's guide. Results: Eighteen studies (1049 children, 10 057 adults) met the inclusion criteria. The risk of bias was high in all but one study. Low evidence supports the position that AIT prevents the onset of new allergen sensitizations, with 10 of 18 studies reporting a reduction in the onset of new sensitizations in patients treated with AIT vs placebo. Small studies and studies with a shorter follow-up showed the highest benefit of AIT. Conclusions: The overall evidence provides a low-grade level of the evidence supporting the efficacy of AIT in preventing the onset of new allergen sensitizations, but high-quality studies could change this estimate.

show abstract

“…The standardised sublingual grass allergy immunotherapy tablet (SQ Ò grass SLIT tablet) has been developed for sublingual application in patients with grass pollen-induced rhinoconjunctivitis, and has been investigated in more than 5700 patients in controlled clinical trials in Europe and North America [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18]. It has been approved Europe-wide and was launched in Germany in November 2006.…”

Section: Introductionmentioning

confidence: 99%

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Schwab¹,

Wolf

Schnitker

et al. 2018

Pulm Ther

View full text Add to dashboard Cite

Introduction: Intra-seasonal start of treatment with the SQ Ò grass sublingual immunotherapy (SLIT) tablet (GRAZAX Ò , ALK, Denmark) has been previously demonstrated to be well-tolerated. The objective of our study was to investigate the tolerability of intra-seasonal start of treatment comparing patients treated by allergists and general practitioners experienced in treatment of allergy (GPs). Methods: In a non-interventional, open-label, observational study, data on intra-seasonal start

show abstract

SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial

Cited by 454 publications

References 31 publications

Mechanisms of Peptide Immunotherapy in Allergic Airways Disease

Mechanisms of Peptide Immunotherapy in Allergic Airways Disease

Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Intra-Seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet Routinely Applied by Allergy Specialists and General Practitioners with Experience in Treatment of Allergy: A Non-Interventional Observational Study

Contact Info

Product

Resources

About